Population
hypersensitivity
HYPERSENSITIVITY, INTRAOCULAR PRESSURE, ADVERSE EFFECT, SYMPATHOMIMETIC
The study inclusion criteria were consented adults (≥ 18-years-old) with advanced life-limiting illnesses known to palliative care services, screened positive with Patient Health Questionnaire-2 (PHQ-2) scores ≥ 3 [The exclusion criteria, in brief, were: Australian-modified Karnofsky Performance scale (AKPS) score = 10; methylphenidate use in the last four weeks; changes to anti-depressant doses in the last two weeks before the commencement of ketamine; ketamine use in the last four weeks; previous significant adverse effect or hypersensitivity to ketamine; concurrent phenobarbitone use; factors of increased risk of intracranial pressure, sympathomimetic response, and intraocular pressure as detailed in the protocol paper [